Corvus Pharmaceuticals
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CRVS and other ETFs, options, and stocks.About CRVS
Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor.
CRVS Key Statistics
Stock Snapshot
As of today, Corvus Pharmaceuticals(CRVS) shares are valued at $19.95. The company's market cap stands at 1.6B, with a P/E ratio of -15.05.
On 2026-01-20, Corvus Pharmaceuticals(CRVS) stock traded between a low of $7.52 and a high of $22.17. Shares are currently priced at $19.95, which is +165.3% above the low and -10.0% below the high.
Corvus Pharmaceuticals(CRVS) shares are trading with a volume of 83.88M, against a daily average of 1.74M.
During the past year, Corvus Pharmaceuticals(CRVS) stock moved between $2.54 at its lowest and $22.17 at its peak.
During the past year, Corvus Pharmaceuticals(CRVS) stock moved between $2.54 at its lowest and $22.17 at its peak.
CRVS News
Corvus Pharmaceuticals (NASDAQ:CRVS), an immuno-oncology and dermatology drug developer, closed Tuesday at $21.41, up 165.96%. The stock moved higher after Phas...
Corvus Pharmaceuticals (CRVS) announced that it has commenced an underwritten public offering of $150M of shares of its common stock and, in lieu of common stoc...
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) on Tuesday shared data from cohort 4 of the Phase 1 trial evaluating soquelitinib in patients with moderate-to-severe...
Analyst ratings
100%
of 7 ratingsMore CRVS News
U.S. stocks were lower, with the Dow Jones falling around 700 points on Tuesday. Shares of Corvus Pharmaceuticals Inc (NASDAQ:CRVS) rose sharply during Tuesday...
Claim 50% Off TipRanks Premium Corvus Pharmaceuticals ( (CRVS) ) has issued an update. On January 20, 2026, Corvus Pharmaceuticals reported positive data from...